Skip to content
This initiative includes a R500-million ($26.4 million) invoice financing facility and a R100-million ($5.3 million) working capital facility.
With a current net worth of $10.7 billion, Oppenheimer ranks 223rd on the global wealth list.
Attridge’s recent financial triumph is attributed to the recent surge in Aspen Pharmacare’s shares on the Johannesburg Stock Exchange (JSE).
Malherbe, Remgro’s non-executive co-deputy chairman, is one of Remgro’s largest individual shareholders with a holding of 1,178,995 ordinary shares.
Since its 2021 demerger from Anglo-American, Thungela has undergone significant expansion under Ndlovu.
Gore expressed confidence in penetrating the U.S. market further, leveraging the success and innovation that Discovery has pioneered in the wellness space.
Under Titi’s leadership, Investec has demonstrated resilience and growth despite challenging market conditions.
This increase cements Saad’s position in the South African business scene, placing him among the leading investors on the JSE.
The announcement comes in the wake of Jooste’s tragic demise, which occurred on Thursday, a day after the FSCA levied a penalty of $25 million against him.
The $155.9-million cash purchase consideration for Reldan was financed through a $500-million senior unsecured guaranteed convertible bond issued in November 2023.
The circumstances surrounding Jooste’s death remain under investigation, with authorities confirming that he was found with a gunshot wound to the head.
Shoprite, boasting more than 2,900 stores across Africa, is partly owned by South African billionaire Christo Wiese, who holds an 11.63-percent stake in the retailer.
Sun International CEO Anthony Leeming affirmed that the capital expenditure will be funded from the group’s cash flows
Calisto’s stake has increased by $25.49 million from $579.68 million on March 15 to $605.17 million at the time of drafting this report.
The surge in Soon-Shiong’s net worth in 2024 highlights the success of his investments, particularly in biotech firm ImmunityBio.
The group’s interim results for the first half of the 2024 fiscal year showcase a headline earnings figure amounting to $172.4 million.